Business
IMMUPHARMA AT BIO-EUROPE SPRING 2024
IMMUPHARMA AT BIO-EUROPE SPRING 2024.
About this update from Immupharma Plc
[{"type":"text","content":"\n\nRNS REACH |14 March 2024\n \n \n\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nIMMUPHARMA AT BIO-EUROPE SPRING 2024\n18-20 March 2024 | Barcelona\n \nImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Europe Spring. The event will be held between 18-20 March 2024, in Barcelona.\n \nBIO-Europe Spring is the premier springtime partnering event, designed to provide biotechnology companies with the opportunity to present to and connect with investors together with the global biopharma community.\n \nCommenting on the event, Tim McCarthy, CEO of ImmuPharma said: \"Following on from our recent announcements, including moving our lead asset P140 for SLE (Lupuzor™) forward, with our appointed CRO, Simbec-Orion, in parallel with our CIDP program, we are delighted to have BIO-Europe as the next key platform in 2024 to present our unique portfolio to key industry and investment specialists. Our focus will be to secure partnering opportunities across our programs including our P140 platform and our earlier stage but highly exciting anti-infective asset, BioAMB.\"\n \n\n\n\n\nFor further information please contact: \n \n\n\n\n\nImmuPharma PLC (www.immupharma.co.uk)\n \nTim McCarthy, Chief Executive Officer\nLisa Baderoon, Head of Investor Relations\n\n\n+44 (0) 207 206 2650\n \n+ 44 (0) 7721 413496\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nSPARK Advisory Partners Limited (NOMAD)\nNeil Baldwin\n \nStanford Capital Partners (Joint Broker)\nPatrick Claridge, Bob Pountney\n \nSI Capital (Joint Broker)\nNick Emerson\n\n\n \n+44 (0) 203 368 3550\n \n \n+44 (0) 203 650 3650\n \n \n+44 (0) 1483 413500\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nNotes to Editors\n \nAbout ImmuPharma PLC\nImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140/SLE (Lupuzor™), P140 \"restores\" the immune system back to normal, by enabling tolerogenic antigen presenting cells to function properly. P140 is not an immunosuppressant unli...